|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 The American Thoracic Society Pulmonary Arterial HypertensionUniversity of California, San Diego, School of Medicine, La Jolla, California Correspondence and requests for reprints should be addressed to Lewis J. Rubin, M.D., University of California, San Diego, School of Medicine, 9300 Campus Point Drive, La Jolla, CA 92037. E-mail: ljrubin{at}ucsd.edu ABSTRACT Pulmonary arterial hypertension (PAH) is a term used to classify a variety of conditions that have in common an injury to the pulmonary vasculature that produces elevations in pulmonary arterial pressure. There have been considerable advances in our understanding of the pathogenesis and treatment of PAH over the past decade. The article reviews the classification of diseases associated with PAH, the current understanding of its pathogenesis, and the contemporary approach to therapy.
Key Words: endothelin prostacyclin pulmonary hypertension This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||